The study involves the use of benfotiamine, which is taken as an oral tablet, and thioctic acid, also known as alpha-lipoic acid. One group will take the combination of these two substances, while other groups will take the individual medications to compare their effects. The medications used for comparison include Benfogamma Forte and Thiogamma.

During the study, individuals will follow a treatment plan for a period of 16 weeks. The process is designed to be double-blind, meaning that neither the participants nor the researchers know which specific treatment is being administered to each person. This helps to ensure that the results are objective and not influenced by expectations.

The purpose of this study is to evaluate how well TRV045 works in reducing pain by using special pain testing methods, including a model that creates temporary mild inflammation on the skin using ultraviolet light. The study is designed as a four-way cross-over trial, which means that participants will receive different treatments in different periods, allowing researchers to compare the effects of the medicine against placebo in the same individuals. This approach helps to better understand whether the medicine provides pain relief.

During the study, healthy adult volunteers between 18 and 55 years of age will take part in testing sessions where they will receive either TRV045 capsules or placebo at different times. The medicine will be given by mouth, with a maximum daily amount of 300 milligrams and a total maximum amount of 400 milligrams over the treatment period. Researchers will measure pain responses using various testing methods and will also monitor the safety of the medicine by checking for any unwanted effects. The study will also measure how the body processes the medicine by taking blood samples to see how much of the drug is present in the bloodstream at different times.

Participants in this study will receive either the capsaicin patch or the placebo patch applied to their skin at different time points during the study. The study will examine changes in nerve fiber density in the skin by taking small skin samples called biopsies. These tiny samples allow researchers to count and measure the nerve fibers under a microscope. The study will also assess changes in pain levels, various symptoms of nerve damage such as burning or tingling sensations, quality of life, and how the skin responds to different sensations like temperature and touch. Additionally, blood flow in the small vessels of the skin and oxygen levels in the tissue will be measured.

The study involves multiple visits to the study center over approximately 35 weeks. During this time, participants will be asked to maintain their current pain and diabetes medications unchanged. Researchers will monitor any side effects or unwanted reactions that may occur during the treatment. The study will also track whether participants need additional pain medication and how often they use it. Various questionnaires and physical tests will be performed throughout the study to measure changes in symptoms and nerve function.

The medication being tested is given as a subcutaneous injection (an injection under the skin) once weekly. During the study, participants will receive either CagriSema or placebo. The study will measure how well the medication works by tracking changes in pain levels that participants experience.

Participants will use a special rating scale to record their pain levels throughout the study. The research will also look at other health measures such as blood sugar control, blood pressure, body weight, and various blood tests to understand how the medication affects the body. The safety of the medication will be monitored by tracking any side effects that may occur during the treatment.

The purpose of the study is to evaluate how well different doses of VX-993 can reduce pain in people with diabetic peripheral neuropathy and to assess its safety. Participants will take the medication orally, and the study will last for up to 12 weeks. During this time, participants will be monitored for any changes in their pain levels and any side effects they might experience. The study will also compare the effects of VX-993 with those of pregabalin to see which is more effective in managing pain.

Throughout the study, participants will have regular check-ins to track their progress and ensure their safety. The main goal is to see if VX-993 can significantly reduce pain compared to the placebo and pregabalin. The study will also look at how well participants tolerate the medication, considering any adverse effects, changes in laboratory test results, and vital signs. This research aims to provide a better understanding of how VX-993 can be used to help people with diabetic peripheral neuropathy manage their pain more effectively.

The purpose of the study is to evaluate how effective and safe the medical cannabis aerosol is when used as an additional treatment for managing pain in patients with diabetic peripheral neuropathic pain. Participants in the study will be randomly assigned to one of four groups, each receiving different doses of the cannabis aerosol or the placebo. The treatment will be administered three times a day over a period of 15 weeks. Throughout the study, participants will be monitored to assess changes in their pain levels and any side effects they may experience.

By participating in this study, researchers aim to gather valuable information on whether the medical cannabis aerosol can help reduce pain intensity in patients with diabetic peripheral neuropathic pain. The findings from this study could potentially lead to new treatment options for individuals suffering from this condition, improving their quality of life and pain management strategies.

The purpose of the study is to determine if LY3556050 is more effective than a placebo in managing pain for individuals with Diabetic Peripheral Neuropathy. Participants in the study will be randomly assigned to receive either the medication or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This approach is known as a double-blind study, which helps ensure the results are unbiased.

Throughout the study, participants will take the medication or placebo orally, and their pain levels will be monitored over time. The study aims to find out if different doses of LY3556050 can provide better pain relief compared to the placebo. The trial is expected to continue until early 2025, with the goal of improving treatment options for those suffering from pain due to Diabetic Peripheral Neuropathy.

The purpose of the study is to investigate how effective and safe these injections are for people experiencing this type of pain. Participants in the study will receive either the actual treatment or a placebo, which is a substance with no active medication, to compare the effects. The study will last for about 24 weeks, during which participants will have regular check-ups to monitor their pain levels and overall health.

Throughout the study, various aspects of the participants’ health will be assessed, including their muscle strength, quality of life, and any changes in their pain symptoms. This will help researchers understand the potential benefits and any side effects of the treatment. The study aims to provide valuable information that could lead to better management of diabetic neuropathic pain in the future.

The purpose of the study is to evaluate how effective eptinezumab is in decreasing pain levels over a period of 24 weeks. Participants in the study will receive either the medication or a placebo, and their pain levels will be monitored and recorded regularly. The study aims to compare the pain relief experienced by those receiving eptinezumab with those receiving the placebo.

Throughout the study, participants will be asked to keep a diary to record their pain levels every morning. This information will help researchers understand how the treatment affects pain over time. The study will also look at other aspects of pain relief, such as the severity of neuropathic pain and the overall level of pain relief experienced at different points during the study.

Participants in the study will receive either the AP707 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will be conducted over several weeks, with regular assessments to monitor changes in pain levels and overall well-being. The goal is to determine if AP707 can provide significant relief from pain compared to the placebo.

Throughout the trial, participants will be asked to report their pain levels and any changes in their condition. The study will also track any side effects or adverse events to ensure the safety of the treatment. By the end of the study, researchers hope to gather valuable information about the potential benefits of AP707 for those suffering from chronic pain due to diabetic polyneuropathy.

The purpose of the study is to assess how well GSK3858279 works in managing pain associated with DPNP. Participants in the study will receive either the new treatment or a placebo. The study will last for a period of 12 weeks, during which participants will be monitored to see how their pain levels change over time. The study aims to provide valuable information on the safety and potential benefits of this new treatment for people suffering from DPNP.

Throughout the study, participants will receive regular check-ups and assessments to ensure their well-being and to gather data on the treatment’s effects. This trial is an important step in exploring new options for managing pain in individuals with diabetic nerve pain, potentially leading to improved quality of life for those affected by this condition.

The purpose of the study is to evaluate how effective ODM-111 is in managing pain associated with diabetic peripheral neuropathy. Participants in the study will receive either ODM-111 or a placebo, and their pain levels will be monitored over a period of six weeks. The medication is taken orally in the form of tablets. Throughout the study, participants will be asked to record their daily pain levels using a simple numerical scale to help researchers assess any changes in pain intensity.

In addition to ODM-111, the study will also involve the use of Para-Tabs, which contain paracetamol, a common pain reliever. The study aims to provide valuable information on the potential benefits of ODM-111 for individuals suffering from chronic pain due to diabetic peripheral neuropathy, with the hope of improving treatment options for this condition.